Breakthrough Preclinical Results: MIRA Pharmaceuticals’ Ketamir-2 Surpasses Leading Neuropathic Pain Treatments

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) reports that its novel oral ketamine analog, Ketamir-2, has outperformed FDA-approved neuropathic pain treatments Gabapentin and Pregabalin in a recent preclinical study. Conducted on female rats with nerve-induced neuropathy, the study showed that low doses of Ketamir-2 provided significant pain relief by Day 15. By Day 22, Ketamir-2 was up to 112% more effective than Pregabalin and 70% more effective than Gabapentin.

These findings offer hope for patients seeking non-opioid solutions to neuropathic pain. Unlike current treatments, Ketamir-2 is non-habit forming and is expected to have fewer side effects, such as cognitive impairment and weight gain. The company is preparing to submit an Investigational New Drug (IND) application by the end of this year and aims to begin Phase 1 clinical trials in early 2025. MIRA is also exploring Ketamir-2’s potential for treating PTSD and depression, further expanding its therapeutic possibilities.

CEO Erez Aminov stated, “We are fully committed to bringing this breakthrough drug to patients as quickly as possible while backing everything we do with strong science.  Ketamir-2 has the potential not only to address neuropathic pain but also to make a significant impact in the treatment of PTSD and depression. Our goal is to ensure that those who need it most have access to this innovative treatment as soon as possible.”